Shell Companies
Compare Stocks
4 / 10Stock Comparison
DMAA vs HCAI vs IIPR vs APCX
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
REIT - Industrial
Software - Infrastructure
DMAA vs HCAI vs IIPR vs APCX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Shell Companies | Industrial - Machinery | REIT - Industrial | Software - Infrastructure |
| Market Cap | $111M | $13M | $1.64B | $14M |
| Revenue (TTM) | $0.00 | $41M | $263M | $787K |
| Net Income (TTM) | $6M | $1M | $120M | $-7M |
| Gross Margin | — | 14.0% | 60.3% | 57.1% |
| Operating Margin | — | 5.5% | 46.7% | -10.0% |
| Forward P/E | — | 8.0x | 13.5x | — |
| Total Debt | $662.00 | $12M | $394M | $147K |
| Cash & Equiv. | $1K | $29K | $48M | $868K |
DMAA vs HCAI vs IIPR vs APCX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Drugs Made In Ameri… (DMAA) | 100 | 106.3 | +6.3% |
| Hauchen AI Parking … (HCAI) | 100 | 8.7 | -91.3% |
| Innovative Industri… (IIPR) | 100 | 79.6 | -20.4% |
| AppTech Payments Co… (APCX) | 100 | 94.7 | -5.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DMAA vs HCAI vs IIPR vs APCX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DMAA lags the leaders in this set but could rank higher in a more targeted comparison.
HCAI carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 19.4%, EPS growth -4.2%, 3Y rev CAGR 69.2%
- Lower volatility, beta 0.34, Low D/E 41.5%, current ratio 2.58x
- Beta 0.34, current ratio 2.58x
- 19.4% revenue growth vs APCX's -45.2%
IIPR is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 9 yrs, beta 0.91, yield 13.3%
- 439.9% 10Y total return vs DMAA's 6.4%
- 45.6% margin vs APCX's -9.1%
- 13.3% yield; 9-year raise streak; the other 3 pay no meaningful dividend
APCX is the clearest fit if your priority is momentum.
- +45.3% vs HCAI's -94.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.4% revenue growth vs APCX's -45.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 45.6% margin vs APCX's -9.1% | |
| Stability / Safety | Beta 0.34 vs APCX's 1.27 | |
| Dividends | 13.3% yield; 9-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +45.3% vs HCAI's -94.7% | |
| Efficiency (ROA) | 5.1% ROA vs APCX's -115.0%, ROIC 4.3% vs -183.2% |
DMAA vs HCAI vs IIPR vs APCX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
DMAA vs HCAI vs IIPR vs APCX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IIPR leads in 4 of 6 categories
HCAI leads 1 • DMAA leads 1 • APCX leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
IIPR leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IIPR and DMAA operate at a comparable scale, with $263M and $0 in trailing revenue. IIPR is the more profitable business, keeping 45.6% of every revenue dollar as net income compared to APCX's -9.1%. On growth, APCX holds the edge at +4.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $41M | $263M | $787,000 |
| EBITDAEarnings before interest/tax | -$726,546 | — | $197M | -$7M |
| Net IncomeAfter-tax profit | $6M | — | $120M | -$7M |
| Free Cash FlowCash after capex | -$414,132 | — | $144M | -$7M |
| Gross MarginGross profit ÷ Revenue | — | +14.0% | +60.3% | +57.1% |
| Operating MarginEBIT ÷ Revenue | — | +5.5% | +46.7% | -10.0% |
| Net MarginNet income ÷ Revenue | — | +3.7% | +45.6% | -9.1% |
| FCF MarginFCF ÷ Revenue | — | +3.7% | +54.7% | -8.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -72.8% | -3.8% | +4.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -62.7% | -1.0% | +34.8% |
Valuation Metrics
HCAI leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 8.0x trailing earnings, HCAI trades at a 45% valuation discount to IIPR's 14.6x P/E. On an enterprise value basis, HCAI's 8.0x EV/EBITDA is more attractive than DMAA's 9999.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $111M | $13M | $1.6B | $14M |
| Enterprise ValueMkt cap + debt − cash | $111M | $25M | $2.0B | $13M |
| Trailing P/EPrice ÷ TTM EPS | -189.29x | 8.03x | 14.58x | -1.13x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 13.49x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 3.89x | — |
| EV / EBITDAEnterprise value multiple | 9999.00x | 7.96x | 10.01x | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.32x | 6.16x | 49.58x |
| Price / BookPrice ÷ Book value/share | — | 0.43x | 0.88x | 1.84x |
| Price / FCFMarket cap ÷ FCF | — | 8.63x | 9.37x | — |
Profitability & Efficiency
IIPR leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
IIPR delivers a 6.4% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-5 for APCX. APCX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCAI's 0.42x. On the Piotroski fundamental quality scale (0–9), HCAI scores 7/9 vs DMAA's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +5.5% | +6.4% | -5.1% |
| ROA (TTM)Return on assets | +2.4% | +3.0% | +5.1% | -115.0% |
| ROICReturn on invested capital | — | +4.2% | +4.3% | -183.2% |
| ROCEReturn on capital employed | — | +7.0% | +5.8% | -194.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.42x | 0.21x | 0.03x |
| Net DebtTotal debt minus cash | $661 | $12M | $346M | -$721,000 |
| Cash & Equiv.Liquid assets | $1,351 | $28,654 | $48M | $868,000 |
| Total DebtShort + long-term debt | $662 | $12M | $394M | $147,000 |
| Interest CoverageEBIT ÷ Interest expense | — | 4.00x | 6.67x | -10.21x |
Total Returns (Dividends Reinvested)
IIPR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DMAA five years ago would be worth $10,643 today (with dividends reinvested), compared to $1,042 for HCAI. Over the past 12 months, APCX leads with a +45.3% total return vs HCAI's -94.7%. The 3-year compound annual growth rate (CAGR) favors IIPR at 4.8% vs HCAI's -52.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.1% | +33.8% | +19.6% | +20.2% |
| 1-Year ReturnPast 12 months | +5.0% | -94.7% | +16.6% | +45.3% |
| 3-Year ReturnCumulative with dividends | +6.4% | -89.6% | +15.1% | -80.1% |
| 5-Year ReturnCumulative with dividends | +6.4% | -89.6% | -46.9% | -80.2% |
| 10-Year ReturnCumulative with dividends | +6.4% | -89.6% | +439.9% | +396.0% |
| CAGR (3Y)Annualised 3-year return | +2.1% | -52.9% | +4.8% | -41.6% |
Risk & Volatility
DMAA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DMAA is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than APCX's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DMAA currently trades 100.0% from its 52-week high vs HCAI's 3.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.00x | 0.34x | 0.91x | 1.27x |
| 52-Week HighHighest price in past year | $10.60 | $318.60 | $61.40 | $0.59 |
| 52-Week LowLowest price in past year | $10.09 | $0.32 | $44.58 | $0.06 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +3.8% | +93.3% | +66.7% |
| RSI (14)Momentum oscillator 0–100 | 71.1 | 62.5 | 56.4 | 35.1 |
| Avg Volume (50D)Average daily shares traded | 166K | 1.5M | 297K | 39K |
Analyst Outlook
IIPR leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
IIPR is the only dividend payer here at 13.30% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Hold | — |
| Price TargetConsensus 12-month target | — | — | $84.67 | — |
| # AnalystsCovering analysts | — | — | 11 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | +13.3% | — |
| Dividend StreakConsecutive years of raises | — | — | 9 | 1 |
| Dividend / ShareAnnual DPS | — | — | $7.62 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.2% | 0.0% |
IIPR leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCAI leads in 1 (Valuation Metrics).
DMAA vs HCAI vs IIPR vs APCX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is DMAA or HCAI or IIPR or APCX a better buy right now?
For growth investors, Hauchen AI Parking Management Technology Holding Co.
, Ltd. (HCAI) is the stronger pick with 19. 4% revenue growth year-over-year, versus -45. 2% for AppTech Payments Corp. (APCX). Hauchen AI Parking Management Technology Holding Co. , Ltd. (HCAI) offers the better valuation at 8. 0x trailing P/E, making it the more compelling value choice. Analysts rate Innovative Industrial Properties, Inc. (IIPR) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DMAA or HCAI or IIPR or APCX?
On trailing P/E, Hauchen AI Parking Management Technology Holding Co.
, Ltd. (HCAI) is the cheapest at 8. 0x versus Innovative Industrial Properties, Inc. at 14. 6x.
03Which is the better long-term investment — DMAA or HCAI or IIPR or APCX?
Over the past 5 years, Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) delivered a total return of +6. 4%, compared to -89. 6% for Hauchen AI Parking Management Technology Holding Co. , Ltd. (HCAI). Over 10 years, the gap is even starker: IIPR returned +439. 9% versus HCAI's -89. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DMAA or HCAI or IIPR or APCX?
By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus AppTech Payments Corp. 's 1. 27β — meaning APCX is approximately Infinity% more volatile than DMAA relative to the S&P 500. On balance sheet safety, AppTech Payments Corp. (APCX) carries a lower debt/equity ratio of 3% versus 42% for Hauchen AI Parking Management Technology Holding Co. , Ltd. — giving it more financial flexibility in a downturn.
05Which is growing faster — DMAA or HCAI or IIPR or APCX?
By revenue growth (latest reported year), Hauchen AI Parking Management Technology Holding Co.
, Ltd. (HCAI) is pulling ahead at 19. 4% versus -45. 2% for AppTech Payments Corp. (APCX). On earnings-per-share growth, the picture is similar: AppTech Payments Corp. grew EPS 65. 3% year-over-year, compared to -28. 8% for Innovative Industrial Properties, Inc.. Over a 3-year CAGR, HCAI leads at 69. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DMAA or HCAI or IIPR or APCX?
Innovative Industrial Properties, Inc.
(IIPR) is the more profitable company, earning 43. 0% net margin versus -32. 4% for AppTech Payments Corp. — meaning it keeps 43. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIPR leads at 46. 7% versus -34. 6% for APCX. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — DMAA or HCAI or IIPR or APCX?
In this comparison, IIPR (13.
3% yield) pays a dividend. DMAA, HCAI, APCX do not pay a meaningful dividend and should not be held primarily for income.
08Is DMAA or HCAI or IIPR or APCX better for a retirement portfolio?
For long-horizon retirement investors, Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00)). Both have compounded well over 10 years (DMAA: +6. 4%, APCX: +396. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between DMAA and HCAI and IIPR and APCX?
These companies operate in different sectors (DMAA (Financial Services) and HCAI (Industrials) and IIPR (Real Estate) and APCX (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DMAA is a small-cap quality compounder stock; HCAI is a small-cap high-growth stock; IIPR is a small-cap deep-value stock; APCX is a small-cap quality compounder stock. IIPR pays a dividend while DMAA, HCAI, APCX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.